Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. The European respiratory journal, 39(1), 172–179.
Nos publications
Depuis sa création, l’Institut Roche a mis son expertise au profit de nombreuses publications scientifiques.
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 22(3), 575–581.